Bioocus - 2025 Company Profile & Competitors

Q: Where is Bioocus located?

Bioocus is located in Beijing, China .

Bioocus is an unfunded company based in Beijing (China), founded in 2022. It operates as a Provider of cellular immunotherapy and gene therapy treatments. Bioocus has not raised any funding yet. The company has 319 active competitors, including 86 funded and 61 that have exited. Its top competitors include companies like BeiGene, Vir Biotechnology and Magenta Therapeutics.

Company Details

Provider of cellular immunotherapy and gene therapy treatments. This entity offers CAR-T therapy for various blood cancers, including leukemia and lymphoma, as well as treatments for thalassemia and sickle cell anemia. Additional therapies include TILs and NK cell therapy for specific cancers and autoimmune diseases. The company collaborates with medical centers to deliver these advanced treatments. Its services encompass the full spectrum of care, from initial consultation to ongoing patient monitoring.

Website
Social
Phone Number: +86

Key Metrics

Founded Year

2022

Location

Beijing, China

Stage

Unfunded

Ranked

343^rd among 369 competitors

Similar Companies

BeiGene &

Bioocus has not raised any funding rounds yet.

Top competitors of Bioocus include BeiGene, Vir Biotechnology and Magenta Therapeutics. Here is the list of Top 10 competitors of Bioocus, ranked by 秘密研究所 score :

Overall Rank	Company Details	Short Description	Total Funding	Investors	秘密研究所 Score
1st	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	T. Rowe Price, Temasek听&补尘辫;听	84/100
2nd	Vir Biotechnology 2017, San Francisco (United States), Public	Developer of therapeutics for the treatment of infectious diseases	$216M	Alta Partners, Arch Venture Partners听&补尘辫;听	75/100
3rd	Magenta Therapeutics 2016, Cambridge (United States), Public	Developer of stem cell-based therapies for autoimmune disease, genetics blood disorders and cancer	$150M	Atlas Venture, Access Industries听&补尘辫;听	73/100
4th	Cidara Therapeutics 2013, San Diego (United States), Public	Developer of novel anti-infectives for infectious diseases (bacterial and fungal)	$78.4M	InterWest Partners, Aisling Capital听&补尘辫;听	73/100
5th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$806M	Temasek, Janus Henderson Investors听&补尘辫;听	72/100
6th	Freeline 2015, Stevenage (United Kingdom), Acquired	Provider of gene therapy platform for treating chronic diseases	$274M	Frazier Healthcare Partners, Novo Holdings听&补尘辫;听	70/100
7th	Decibel Therapeutics 2015, Cambridge (United States), Acquired	Developer of new medicines to protect, repair and restore hearing capacity	$170M	Foresite Capital, Orbimed听&补尘辫;听	69/100
8th	Blue Rock Therapeutics 2016, Boston (United States), Acquired	Stem cell therapies for cardiovascular and neurological diseases	$225M	Versant Ventures, JLABS听&补尘辫;听	68/100
9th	Serum Institute of India 1966, Pune (India), Funding Raised	Manufacturer of vaccines and immuno-biological drugs for infectious diseases	-	Adurjee and Bros, Global Health Investment Fund听&补尘辫;听	69/100
10th	Keros Therapeutics 2016, Lexington (United States), Public	Developer of small molecules to treat hematologic and musculoskeletal disorders	$90M	Venrock, Foresite Capital听&补尘辫;听	67/100
343rd	2022, Beijing (China), Unfunded	Provider of cellular immunotherapy and gene therapy treatments	-	-	11/100